Actos Product Liability Lawsuit Set for Trial February 2013, Parker Waichman LLP Reports

Share Article

Parker Waichman LLP is reporting that an Actos product liability lawsuit in California is scheduled to go to trial on February 19, 2013. The Honorable Kenneth R. Freeman is presiding over the case. Actos is the subject of thousands of suits in the United States, many of which allege that the Type 2 diabetes drug caused bladder cancer.

News Image
Last June, the U.S. Food and Drug Administration (FDA) announced a label update on Actos warning users about the apparent risk of bladder cancer after taking the drug for more than one year.

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, is giving an update on the pre-trial proceedings for an Actos lawsuit filed in the Superior Court of the State of California for the County of Los Angeles. According to the proposed order setting pretrial schedule, the case is set to go to trial on February 19, 2013 at 9:00 a.m. The order setting also schedules a status conference for January 7, 2013, where the status of the case and potential motion for change of venue will be discussed. The case is Jack Cooper, et al. v. Takeda Pharmaceuticals America, Inc., et al., San Francisco Superior Court, No. CGC-12-518535. The Honorable Kenneth R. Freeman is presiding over the litigation.

Actos is a Type 2 diabetes drug that has sparked some 10,000 lawsuits alleging that the drug caused bladder cancer, according to a report in Bloomberg Businessweek. Separate from this case, many have been filed in federal court under the Actos multidistrict litigation referred to as In Re: Actos (Pioglitazone) Products Liability Litigation (MDL No. 6:11-md-2299). Proceedings for the MDL are taking place in U.S. District Court for the Western District of Louisiana, before the Honorable Rebecca Doherty. Jerrold S. Parker, founding partner of Parker Waichman LLP, has been appointed to the Plaintiffs’ Steering Committee.

Last June, the U.S. Food and Drug Administration (FDA) announced a label update on Actos warning users about the apparent risk of bladder cancer after taking the drug for more than one year. The warning was based on data from ongoing 10 year epidemiological study by Kaiser Permanente. At around the same time, sale of Actos was suspended in France and Germany due to the bladder cancer risks.

A recent study published in the Journal for the National Cancer Institute supported the link between bladder cancer and long-term use of Actos. Over the summer, the Canadian Medical Journal Association published a study showing that the risk of bladder cancer increased 22 percent with the use of Actos. The analysis was based on data from over 2.6 million patients. According to the Institute for Safe Medication Practices’ most recent QuarterWatch Report, which focused on Actos and three other “suspect” drugs, the FDA has received over 1,000 reports of bladder cancer since last January.

Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Gary Falkowitz, Managing Attorney
Follow us on
Visit website